Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
about
Chimeric antigen receptor T-cell therapy for solid tumorsMesothelin-Targeted CARs: Driving T Cells to Solid TumorsDiacylglycerol kinase α establishes T cell polarity by shaping diacylglycerol accumulation at the immunological synapseThe Immunomodulatory Functions of Diacylglycerol Kinase ζDiacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in CancerDiacylglycerol Kinases in T Cell Tolerance and Effector FunctionLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesMolecular Pathways: Targeting Diacylglycerol Kinase Alpha in CancerTargeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8+ T Cells with Broad Antitumor Capacity.The ζ isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling.Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumorsDysregulated choline metabolism in T-cell lymphoma: role of choline kinase-α and therapeutic targeting.TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.Annular PIP3 accumulation controls actin architecture and modulates cytotoxicity at the immunological synapse.Chimeric antigen receptor T cells: a novel therapy for solid tumors.CD28z CARs and armored CARsOvercoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road.Redundant and specialized roles for diacylglycerol kinases α and ζ in the control of T cell functions.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis.Chimeric antigen receptors: driving immunology towards synthetic biology.Diacylglycerol kinase ζ limits the polarized recruitment of diacylglycerol-enriched organelles to the immune synapse in T cells.CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.Unexpected positive control of NFκB and miR-155 by DGKα and ζ ensures effector and memory CD8+ T cell differentiation.Diacylglycerol Kinase ζ Is a Target To Enhance NK Cell FunctionEnhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.Deconstructing Lipid Kinase Inhibitors by Chemical Proteomics.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.TGF-β in T Cell Biology: Implications for Cancer Immunotherapy.Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies
P2860
Q26750908-B30E9AC7-CED1-4645-A674-D34BE507CE67Q26778759-099A0A81-DAE3-446C-A095-9CFDB08113F9Q27329909-0452F333-8364-4697-BE45-B95AFF3404F0Q28069781-9A78B9D7-5516-4E6E-B340-70E5F6C12AE0Q28069966-F37F341E-FD26-463D-985D-3E7E3966FD12Q28079616-F58C2DBF-DE1C-43BF-8FD9-CF2EA65E9ACCQ28395597-A2AB09B7-2C23-4E2F-9FF6-900AB8ADADC6Q30278600-4D2E3562-AD0F-446E-8C08-086EEE1B2FF6Q33555573-AFD5D1E1-672E-4706-AE5A-FF4062AA14CEQ33715829-ADD35A03-CA5F-4C8C-86A1-7EB787CC1E21Q33894273-3D86E9C0-D6FF-4078-83BD-5F8341698043Q34052580-9961C30D-365D-4842-8762-5D518FAA309FQ35244854-EACD4210-6E22-41B6-ACB0-071D56F8AC77Q36143408-EEEEA7C0-9383-4AE4-874E-A3F523811EB4Q36963494-C391ECCE-83D8-4C8F-A65B-E97C501EA37BQ37137924-D6435C2D-204D-4EE7-8100-E35B5E485D15Q37322193-6F668650-95DC-4ABB-A9B0-96F5BE90C77CQ37728639-3808C92D-A6BE-483A-9E3A-73EDF1858696Q38199347-E92A6C24-12DD-464D-B060-79713F0CBC27Q38441750-59650A74-B6A1-423B-8E7F-1766A4D3C419Q38447171-63084BE6-DF25-4BEB-9ACB-4006DAE754BDQ38525024-A3FA3B91-49CA-4904-84BA-C313B6CEDCE5Q38564280-CFBF5F95-DCB6-4C33-AE79-34FA916304C4Q38884383-1A20078D-9750-4A34-80FE-F856746D3C10Q39080407-6510C01C-BA2E-458E-9E0B-BB057C2633E8Q39305346-85CA9E2C-6588-4089-A5F6-F964F04B8C2EQ39889227-3A144C5A-846B-490D-A821-FCE6134D9F11Q40637249-1F7E85EB-4C0D-426B-B669-10A7D1974F29Q40895579-FF91E819-7315-496F-A84F-CBF0D7DD1891Q41764893-3F453160-1E0A-4B3F-B589-DB76C09ECE27Q45073422-4244B127-A6B5-46FE-97F3-7F9824381840Q47193084-0A55DAFE-C3A9-4B05-A139-3DE51FEA6D02Q47561397-1E6271F7-60BC-4684-A781-ECF7A6735D4EQ52699883-BC434705-6F1C-4962-893B-0A08324B716EQ53690286-1871AF91-2EED-4F56-9003-FABE491FEA58Q55515390-A58BBCF5-8131-4E62-940D-7FD88ACFDE9AQ58780007-A9CB20DD-2A7C-4BAB-8497-617F8673698E
P2860
Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Enhanced effector responses in ...... ent in diacylglycerol kinases.
@en
type
label
Enhanced effector responses in ...... ent in diacylglycerol kinases.
@en
prefLabel
Enhanced effector responses in ...... ent in diacylglycerol kinases.
@en
P2093
P2860
P1433
P1476
Enhanced effector responses in ...... ent in diacylglycerol kinases.
@en
P2093
Anjana Ranganathan
Carl H June
Edmund K Moon
Gary A Koretzky
Liang-Chuan S Wang
Matthew J Riese
Rohan P Joshi
Steven M Albelda
P2860
P304
P356
10.1158/0008-5472.CAN-12-3874
P407
P577
2013-04-10T00:00:00Z